Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.
disparities
ethnicity
liver cancer
race
survival
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
24
11
2020
revised:
22
12
2020
accepted:
24
12
2020
pubmed:
3
1
2021
medline:
17
3
2022
entrez:
2
1
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States; however, HCC incidence and mortality are not equally distributed among racial and ethnic groups. Our aim was to characterize the direction and magnitude of racial and ethnic disparities in overall survival and early tumor detection among patients with HCC. We searched MEDLINE, EMBASE and Cochrane databases from inception through August 2020 for studies reporting HCC outcomes (early stage presentation and overall survival) by race and ethnicity. We calculated pooled hazard ratios (HRs) and odds ratios (ORs) for each racial and ethnic group (White, Black, Hispanic, Asian) using the DerSimonian and Laird method for a random-effects model. We identified 35 articles comprising 563,097 patients (53.0% White, 17.3% Black, 18.4% Hispanic, 5.0% Asian). Compared with White patients, Black patients had worse survival (pooled HR 1.08; 95% CI, 1.05 - 1.12), whereas Hispanic (pooled HR 0.92; 95% CI, 0.87 - 0.97) and Asian (pooled HR 0.81; 95% CI, 0.73 - 0.88) patients had better survival. Among articles reporting tumor stage (n = 20), Black patients had lower odds of early stage HCC compared with White patients (OR, 0.66; 95% CI, 0.54 - 0.78). Conversely, there was no difference in odds of early HCC detection for Asian (OR, 1.01; 95% CI, 0.97 - 1.05) or Hispanic patients (OR, 0.87; 95% CI, 0.74 - 1.01) compared with White patients. The most common limitation of studies was risk of residual confounding from socioeconomic status and liver dysfunction. There are significant racial and ethnic disparities in HCC prognosis in the United States, with Black patients having worse overall survival and Hispanic and Asian patients having better overall survival compared with White patients. Interventions are needed to reduce disparities in early HCC detection to improve HCC prognosis.
Sections du résumé
BACKGROUND AND AIMS
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States; however, HCC incidence and mortality are not equally distributed among racial and ethnic groups. Our aim was to characterize the direction and magnitude of racial and ethnic disparities in overall survival and early tumor detection among patients with HCC.
METHODS
We searched MEDLINE, EMBASE and Cochrane databases from inception through August 2020 for studies reporting HCC outcomes (early stage presentation and overall survival) by race and ethnicity. We calculated pooled hazard ratios (HRs) and odds ratios (ORs) for each racial and ethnic group (White, Black, Hispanic, Asian) using the DerSimonian and Laird method for a random-effects model.
RESULTS
We identified 35 articles comprising 563,097 patients (53.0% White, 17.3% Black, 18.4% Hispanic, 5.0% Asian). Compared with White patients, Black patients had worse survival (pooled HR 1.08; 95% CI, 1.05 - 1.12), whereas Hispanic (pooled HR 0.92; 95% CI, 0.87 - 0.97) and Asian (pooled HR 0.81; 95% CI, 0.73 - 0.88) patients had better survival. Among articles reporting tumor stage (n = 20), Black patients had lower odds of early stage HCC compared with White patients (OR, 0.66; 95% CI, 0.54 - 0.78). Conversely, there was no difference in odds of early HCC detection for Asian (OR, 1.01; 95% CI, 0.97 - 1.05) or Hispanic patients (OR, 0.87; 95% CI, 0.74 - 1.01) compared with White patients. The most common limitation of studies was risk of residual confounding from socioeconomic status and liver dysfunction.
CONCLUSIONS
There are significant racial and ethnic disparities in HCC prognosis in the United States, with Black patients having worse overall survival and Hispanic and Asian patients having better overall survival compared with White patients. Interventions are needed to reduce disparities in early HCC detection to improve HCC prognosis.
Identifiants
pubmed: 33387668
pii: S1542-3565(20)31725-0
doi: 10.1016/j.cgh.2020.12.029
pmc: PMC8243558
mid: NIHMS1658688
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e267-e288Subventions
Organisme : NCI NIH HHS
ID : R01 CA237659
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD012565
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
Dig Dis Sci. 2020 Jun;65(6):1669-1678
pubmed: 31643036
Am J Public Health. 2019 Jan;109(S1):S16-S20
pubmed: 30699025
Dig Dis Sci. 2008 Feb;53(2):551-5
pubmed: 17562173
Gut. 2021 Feb;70(2):401-407
pubmed: 32398224
Health Serv Res. 2005 Oct;40(5 Pt 2):1658-75
pubmed: 16179001
Am J Gastroenterol. 2013 Aug;108(8):1314-21
pubmed: 23752878
Dig Dis Sci. 2018 Feb;63(2):515-528
pubmed: 29275448
J Clin Oncol. 2016 May 20;34(15):1787-94
pubmed: 27044939
Clin Gastroenterol Hepatol. 2019 Feb;17(3):551-559.e1
pubmed: 29859983
Cancer. 2014 Dec 1;120(23):3683-90
pubmed: 25081065
J Racial Ethn Health Disparities. 2016 Sep 8;:
pubmed: 27631381
Surgery. 2012 Oct;152(4):661-6; discussion 666-7
pubmed: 22935095
Am J Surg. 2017 Jul;214(1):100-104
pubmed: 28624027
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Hepatol Commun. 2018 Dec 03;3(1):52-62
pubmed: 30619994
Clin Gastroenterol Hepatol. 2022 Jan;20(1):9-18
pubmed: 32961340
World J Hepatol. 2017 Mar 8;9(7):391-400
pubmed: 28321275
Transplantation. 2019 Dec;103(12):2531-2538
pubmed: 30951016
J Natl Compr Canc Netw. 2021 May 28;19(9):1063-1071
pubmed: 34077908
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Cancer. 2010 Apr 1;116(7):1801-9
pubmed: 20143441
Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5
pubmed: 16431312
J Hepatocell Carcinoma. 2019 Nov 15;6:167-181
pubmed: 31815112
J Clin Oncol. 2013 Oct 1;31(28):3572-8
pubmed: 23960183
Ann Surg Oncol. 2010 Dec;17(12):3104-11
pubmed: 20585872
Cancer. 2018 Jun 15;124(12):2588-2598
pubmed: 29624631
Aliment Pharmacol Ther. 2020 Aug;52(4):701-709
pubmed: 32598091
Demography. 2015 Feb;52(1):1-14
pubmed: 25550142
Hepatol Commun. 2020 Aug 09;4(10):1541-1551
pubmed: 33024922
Ethn Dis. 2010 Spring;20(2):169-73
pubmed: 20503898
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Hepatol. 2017 Feb;66(2):355-362
pubmed: 27693539
Arch Intern Med. 2007 Oct 8;167(18):1983-9
pubmed: 17923599
Am Surg. 2020 Jul;86(7):865-872
pubmed: 32721171
Surgery. 2020 Jul;168(1):49-55
pubmed: 32414566
Ann Hepatol. 2019 Jan - Feb;18(1):177-186
pubmed: 31113588
Int J Environ Res Public Health. 2016 Dec 14;13(12):
pubmed: 27983668
World J Hepatol. 2018 Nov 27;10(11):849-855
pubmed: 30533185
Am J Gastroenterol. 2019 Jan;114(1):80-88
pubmed: 30333542
Cancer. 2014 May 1;120(9):1401-8
pubmed: 24477988
Surgery. 2015 Nov;158(5):1244-51
pubmed: 25958069
Pathology. 2007 Apr;39(2):228-34
pubmed: 17454753
Hepatology. 2020 Nov;72(5):1654-1665
pubmed: 32017165
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48
pubmed: 30670200
Cancer Causes Control. 2018 Sep;29(9):833-844
pubmed: 30030669
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
J Gastrointest Oncol. 2015 Jun;6(3):259-67
pubmed: 26029452
J Gastrointest Oncol. 2018 Apr;9(2):316-325
pubmed: 29755771
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Hepatology. 2021 Feb;73(2):713-725
pubmed: 32383272
Curr Epidemiol Rep. 2017 Mar;4(1):31-37
pubmed: 28255530
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666
pubmed: 31401364
Hepatol Int. 2019 Sep;13(5):609-617
pubmed: 31372942
Am J Med. 2015 Jan;128(1):90.e1-7
pubmed: 25116425
Cancer. 2018 Feb 15;124(4):743-751
pubmed: 29072773
Aliment Pharmacol Ther. 2013 Oct;38(7):703-12
pubmed: 23957569
Am J Public Health. 2019 Jan;109(S1):S28-S33
pubmed: 30699015
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):16-28
pubmed: 28108348
Ann Intern Med. 1996 Oct 15;125(8):675-9
pubmed: 8849153
World J Gastroenterol. 2016 Oct 14;22(38):8584-8595
pubmed: 27784971